- Bone Morphogenic Protein Is a Viable Adjunct for Fusion in Minimally Invasive Transforaminal Lumbar Interbody Fusion
-
Siddiqui M, Sta.Ana AR, Yeo W, Yue WM
- KMID: 2362188
- Asian Spine J.
- 2016 Dec;10(6):1091-1099.
- doi: 10.4184/asj.2016.10.6.1091
STUDY DESIGN: Comparison of prospectively collected data of patients undergoing minimally invasive surgery transforaminal lumbar interbody fusion (MIS-TLIF) with and without recombinant human bone morphogenic protein 2 (BMP). PURPOSE: To compare... -
- CITED
-
- Close
- SHARE
-
- Close
- Single-Level Minimally Invasive Transforaminal Lumbar Interbody Fusion Provides Sustained Improvements in Clinical and Radiological Outcomes up to 5 Years Postoperatively in Patients with Neurogenic Symptoms Secondary to Spondylolisthesis
-
Bin Abd Razak HR, Dhoke P, Tay KS, Yeo W, Yue WM
- KMID: 2377753
- Asian Spine J.
- 2017 Apr;11(2):204-212.
- doi: 10.4184/asj.2017.11.2.204
STUDY DESIGN: Retrospective review of prospective registry data. PURPOSE: To determine 5-year clinical and radiological outcomes of single-level instrumented minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) in patients with neurogenic symptoms... -
- CITED
-
- Close
- SHARE
-
- Close
- Elderly Patients Achieving Clinical and Radiological Outcomes Comparable with Those of Younger Patients Following Minimally Invasive Transforaminal Lumbar Interbody Fusion
-
Nikhil N J, Lim JW, Yeo W, Yue WM
- KMID: 2377756
- Asian Spine J.
- 2017 Apr;11(2):230-242.
- doi: 10.4184/asj.2017.11.2.230
STUDY DESIGN: Retrospective analysis of prospective database. PURPOSE: To compare 2-year clinical and radiological outcomes after minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) among “middle-age†(50–64.99 years), “young-old†(65–74.99 years), and... -
- CITED
-
- Close
- SHARE
-
- Close
